AbbVie (NYSE: ABBV) Reports Q2 2026 Earnings Friday July 31 With Total Net Revenues of $17 Billion (+10.2% Year-Over-Year, Beating Consensus by $300 Million), Skyrizi (Risankizumab) Global Net Revenues of $5.505 Billion (+24.4% YoY Reported / +24.0% YoY Operational) and Rinvoq (Upadacitinib) Global Net Revenues of $2.525 Billion (+24.5% YoY Reported / +23.7% YoY Operational); AbbVie Now Expects the Combined Skyrizi and Rinvoq Franchise to Generate Approximately $32 Billion in Peak Annual Sales; Humira Continues Biosimilar-Driven Decline at -35.9% YoY to $756 Million; Neuroscience Portfolio Delivers +20% Growth With Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta All Achieving Double-Digit Sales Growth
AbbVie (NYSE: ABBV) reported Q2 2026 earnings Friday July 31, 2026 before market open with total net revenues of $17 billion (+10.2% year-over-year), beating consensus by $300 million. Skyrizi (risankizumab, IL-23p19 monoclonal antibody for psoriasis, psoriatic arthritis, and inflammatory bowel disease) reached global Q2 net revenues of $5.505 billion (+24.4% YoY reported, +24.0% YoY operational). Rinvoq (upadacitinib, oral JAK1-selective inhibitor for rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease) reached global Q2 net revenues of $2.525 billion (+24.5% YoY reported, +23.7% YoY operational), with Rinvoq on pace for 30% growth in gastroenterology this year. AbbVie now expects the combined Skyrizi and Rinvoq franchise to generate approximately $32 billion in peak annual sales, with management anticipating combined peak sales for Rinvoq in vitiligo and alopecia areata to approach $2 billion. Humira (adalimumab, the anchor immunology franchise before biosimilar competition began in 2023) continued its expected decline at $756 million Q2 revenue, -35.9% YoY reported / -36.1% YoY operational. The neuroscience portfolio delivered approximately 20% Q2 growth with Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta all achieving double-digit sales growth. Full-year 2026 guidance was reiterated at $14.08-14.28 adjusted EPS on approximately $67 billion in revenue.